https://www.lyntonix.com/en/contact.htmlLYNTONIX, INC.https://www.lyntonix.com/en/images/corpimg.png17, Xuzhou Road, Room 936, Taipei, 100 Taiwan$02-3366-8696Lyntonix is a spin-off startup company established in 2025 by the original National Taiwan University (NTU) irritable bowel syndrome (IBS) new drug team; the key members are Professor Ling-Wei Hsin (School of Pharmacy), Professor Linda Yu (Institute of Physiology), and Superintendent Ming-Shian Wu (NTU Hospital).
Our mission is to provide novel, non-addictive solution for various chronic pain for which there is currently no satisfactory clinical treatment, to relieve the physical and mental suffering and stress caused by long-term pain, so that patients can regain a dignified and high-quality daily life.Current goal is focused on developing novel drugs and therapeutic strategies for treating abdominal pain in irritable bowel syndrome (IBS). Lyntonix has identified the mechanism underlined the IBS-related abdominal pain and novel drug target. This breakthrough led to the successful development of LTX-568, a first-in-class drug candidate possessing superior analgesic efficacy with excellent safety profile. LTX-568 has the potential to become a first-line treatment for visceral hypersensitivity and can be used to treat abdominal pain across various IBS subtypes, which demonstrating huge market potential. The non-GLP preclinical studies, including pharmacology, pharmacokinetics, and toxicology assessments, have been completed. Lyntonix plans to complete angel-round fundraising in 2025, start the GLP studies, submit IND applications in the United States and Taiwan in 2026, and conduct the Phase I human clinical trial in 2027.
LYNTONIX was founded on March 25, 2025.Correspondence address：17, Xuzhou Road, Room 936, Taipei, 100 Taiwan
